Skip to content

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Research Papers

Filter by Tag

Effectiveness and safety of the BPaL regimen in the Philippines

Publication: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

December 4, 2025

An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines

Publication: IJTLD OPEN

September 10, 2025

A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Publication: Clinical Pharmacokinetics

June 30, 2025

Development, implementation, and evaluation of an innovative clinical trial operations training program for Africa (ClinOps)

Publication: BMC Medical Education

January 24, 2025

Introducing BPaL: Experiences from countries supported under the LIFT-TB project

Publication: PLOS One

November 1, 2024

Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan

Publication: IJTLD Open

November 1, 2024

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

Publication: PLoS One

October 1, 2024

Clofazimine pharmacokinetics in patients with TB: dosing implications

Publication: Journal of Antimicrobial Chemotherapy

August 19, 2024

Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the…

Savings from the introduction of BPaL and BPaLM regimens at the country level

Publication: IJTLD Open

August 1, 2024

1 2 3 4 5 … 7 8 9 10 Next »

About
Why New TB Drugs
R&D
Access
News

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328

Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list

Email Address

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy

Treat 2,037,998 People

In the first fifteen years following BPaL’s approval, more than 2 million people treated for drug-resistant TB will be treated with BPaL/M. This means millions of people will benefit from improved treatment outcomes and experiences.

Restore 5,120,433 healthy life years

When TB doesn’t kill, it often leaves people with long periods of disability. By curing drug-resistant TB faster and more effectively, BPaL/M helps people not only survive, but recover faster, and avoid long term disabilities. That means fewer years lost to illness and more people living fully again, faster. In its first 15 years of approval, BPaL/M will result in people experiencing more than 5 million more healthy years of life.

Save an Additional 191,222 lives

BPaL/M has higher treatment success rates than previous therapies and use of these regimens is rapidly scaling up globally. In its first 15 years of approval, BPaL/M will save an additional 190,000 lives by replacing older treatments with lower success rates.

Save the world $1.29B USD

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people receiving treatment.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.

179,697 more people will complete treatment

Traditionally, many people receiving treatment for drug-resistant TB did not complete therapy. This was often due to the length and side effects of treatments. Those who don’t complete treatment may remain contagious and infect others, as well as suffer increased disability or death. In its first 15 years of approval, BPaL/M will lead to nearly 180,000 additional people completing treatment.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” In its first 15 years of approval, BPaL/M will lead to more than 330,000 additional people with drug-resistant TB being successfully treated.